Jove
Visualize
Contact Us
JoVE
x logofacebook logolinkedin logoyoutube logo
ABOUT JoVE
OverviewLeadershipBlogJoVE Help Center
AUTHORS
Publishing ProcessEditorial BoardScope & PoliciesPeer ReviewFAQSubmit
LIBRARIANS
TestimonialsSubscriptionsAccessResourcesLibrary Advisory BoardFAQ
RESEARCH
JoVE JournalMethods CollectionsJoVE Encyclopedia of ExperimentsArchive
EDUCATION
JoVE CoreJoVE BusinessJoVE Science EducationJoVE Lab ManualFaculty Resource CenterFaculty Site
Terms & Conditions of Use
Privacy Policy
Policies

Related Experiment Videos

A simulation study comparing designs for dose ranging.

L B Sheiner1, Y Hashimoto, S L Beal

  • 1Department of Laboratory Medicine, School of Medicine, University of California, San Francisco.

Statistics in Medicine
|March 1, 1991
PubMed
Summary
This summary is machine-generated.

Related Concept Videos

You might also read

Related Articles

Articles linked to this work by shared authors, journal, and citation graph.

Sort by
Same author

Pharmacodynamic measurements of methyl nicotinate percutaneous absorption.

Pharmaceutical research·2013
Same author

A new Bayesian method to forecast and fine tune individual hemodialysis dose.

Hemodialysis international. International Symposium on Home Hemodialysis·2009
Same author

Ways to fit a PK model with some data below the quantification limit.

Journal of pharmacokinetics and pharmacodynamics·2002
Same author

Selecting reliable pharmacokinetic data for explanatory analyses of clinical trials in the presence of possible noncompliance.

Journal of pharmacokinetics and pharmacodynamics·2001
Same author

The need for mixed-effects modeling with population dichotomous data.

Journal of pharmacokinetics and pharmacodynamics·2001
Same author

Evaluating pharmacokinetic/pharmacodynamic models using the posterior predictive check.

Journal of pharmacokinetics and pharmacodynamics·2001

Dose-escalation designs are superior for drug dose-ranging studies, offering better parameter estimation than parallel-dose designs. They closely match clinical practice while providing robust data, making them a strong alternative to cross-over designs.

Area of Science:

  • Pharmacology
  • Biostatistics
  • Clinical Trial Design

Background:

  • Accurate dose-response parameter knowledge is crucial for determining optimal drug dosages.
  • Current FDA-approved parallel-dose designs offer limited insight into individual dose-response parameter distributions.
  • Alternative designs like cross-over and dose-escalation offer potential improvements.

Purpose of the Study:

  • To compare the parameter estimation performance of parallel-dose, cross-over, and dose-escalation designs.
  • To evaluate these designs under complex dose-response models and study execution challenges.
  • To provide evidence-based recommendations for optimal dose-ranging study designs.

Main Methods:

  • Simulated parameter estimation for three distinct dose-ranging study designs.

Related Experiment Videos

  • Utilized complex and realistic dose-response models.
  • Incorporated potential complications in study execution for robust evaluation.

    • Main Results:

    • The dose-escalation design demonstrated superior performance over the parallel-dose design across considered models.
    • Dose-escalation designs showed performance generally comparable, though slightly less effective than, cross-over designs.
    • The dose-escalation approach balances informative data collection with clinical practice resemblance.

    Conclusions:

    • Dose-escalation designs are highly effective for dose-ranging studies, outperforming parallel-dose designs.
    • Both cross-over and dose-escalation designs are recommended for dose-ranging, depending on clinical context.
    • Dose-escalation designs facilitate the study of representative patient populations while mimicking clinical practice.